IRRAflow® Medical Affairs
This section of the website is intended exclusively for qualified healthcare professionals (HCPs).
2025
Chemical Stability Testing of Solutions for Intraventricular Irrigations via IRRAflow Ventricular Drain System
July 2025 – Hospital Pharmacy
Jeffrey Garavaglia, Anthony DeBastiani, Jessica Peaslee, & Nicholas Brandmeir
This clinical literature is provided for information and educational purposes only. The administration of specific fluids and medications using the IRRAflow Active Fluid Exchange System is not approved by the FDA, and reflects the authors’ clinical opinions and findings. The IRRAflow Active Fluid Exchange System is intended to deliver physician directed fluids, and is not indicated for administration of specific medications. Any medication selection, dosage, and method of administration is determined solely by the treating physician in accordance with their clinical judgment and regulatory requirements.
The FDA cleared indications of the IRRAflow Active Fluid Exchange System are as follows:
The use of IRRAflow Active Fluid Exchange System is indicated when intracranial pressure monitoring is required, and for externally draining intracranial fluid, as a means of reducing intracranial pressure in patients where an external drainage and monitoring system is needed. The IRRAflow Active Fluid Exchange System is also intended to deliver physician directed fluids.
For full information on contraindications and limitations, restrictions, cautions, warnings, or precautions in connection with the use of the IRRAflow Active Fluid Exchange System, please see the product Instructions for Use at https://www.clearpointneuro.com/irraflow/irraflow-eifus/
The following contributors to these publications were paid consultants who received compensation from IRRAS at the time of writing, editing, or contributing to the publications.
Dr. Nicholas Brandmeir - West Virginia University School of Medicine
Dr. Behnam Rezai Jahromi - University of Helsinki
Dr. Sumeet Vadera - University of California Irvine
Dr. Alexandra Paul - Albany Medical Center
Dr. Adnan Siddiqui - University at Buffalo
Jeffrey Garavaglia - West Virginia University School of Medicine
Active Cerebrospinal Fluid Exchange vs External Ventricular Drainage in the Neurocritical Care Unit: An International, Retrospective Cohort Study
June 2025 – Neurosurgery Practice
Behnam Rezai Jahromi, MD, Gracie Monachello, Muhammad Babar Khan, MD, PhD, Johnie O. Hodge, MD, PhD, Jeffrey Garavaglia, PharmD, BCCCP, Ryan C. Turner, MD, PhD, Mika Niemela, MD, PhD, Jari Siironen, MD, PhD, Paivi Tanskanen, MD Alexandra R. Paul, MD, Ammad A. Baig, MD, Ryan M. Hess, MD, Elad I. Levy, MD, MBA, Adnan H. Siddiqui, MD, PhD, & Nicholas J. Brandmeir, MD, MS
This clinical literature is provided for information and educational purposes only. The administration of specific fluids and medications using the IRRAflow Active Fluid Exchange System is not approved by the FDA, and reflects the authors’ clinical opinions and findings. The IRRAflow Active Fluid Exchange System is intended to deliver physician directed fluids, and is not indicated for administration of specific medications. Any medication selection, dosage, and method of administration is determined solely by the treating physician in accordance with their clinical judgment and regulatory requirements.
The FDA cleared indications of the IRRAflow Active Fluid Exchange System are as follows:
The use of IRRAflow Active Fluid Exchange System is indicated when intracranial pressure monitoring is required, and for externally draining intracranial fluid, as a means of reducing intracranial pressure in patients where an external drainage and monitoring system is needed. The IRRAflow Active Fluid Exchange System is also intended to deliver physician directed fluids.
For full information on contraindications and limitations, restrictions, cautions, warnings, or precautions in connection with the use of the IRRAflow Active Fluid Exchange System, please see the product Instructions for Use at https://www.clearpointneuro.com/irraflow/irraflow-eifus/
The following contributors to these publications were paid consultants who received compensation from IRRAS at the time of writing, editing, or contributing to the publications.
Dr. Nicholas Brandmeir - West Virginia University School of Medicine
Dr. Behnam Rezai Jahromi - University of Helsinki
Dr. Sumeet Vadera - University of California Irvine
Dr. Alexandra Paul - Albany Medical Center
Dr. Adnan Siddiqui - University at Buffalo
Jeffrey Garavaglia - West Virginia University School of Medicine
Twist-Drill Craniostomy with Pressure-Controlled Fibrinolytic Irrigation Therapy for the Evacuation of Acute Traumatic Subdural Hematoma in Patients Not Requiring Immediate Craniotomy
May 2025 – Neurosurgery Practice
Marco Bissolo, MD, Roberto Doria-Medina, MD, Theresa Bettina Loidl, MD, Istvan Csók, MD, Mukesch Johannes Shah, MD, MSc, Eva Rohr, MD, Klaus-Jürgen Buttler, MD, Ralf Watzlawick, MD, Christoph Scholz, MD, Jürgen Beck, MD, & Roland Roelz, MD
The following articles/clinical evidence describes some uses of IRRAflow that are not approved by the FDA, and the safety and effectiveness of any unapproved use(s) have not been established.
The FDA cleared indications of the IRRAflow Active Fluid Exchange System are as follows:
The use of IRRAflow Active Fluid Exchange System is indicated when intracranial pressure monitoring is required, and for externally draining intracranial fluid, as a means of reducing intracranial pressure in patients where an external drainage and monitoring system is needed.
For full information on contraindications and limitations, restrictions, cautions, warnings, or precautions in connection with the use of the IRRAflow Active Fluid Exchange System, please see the product Instructions for Use at https://www.clearpointneuro.com/irraflow/irraflow-eifus/
The following contributors to these publications were paid consultants who received compensation from IRRAS at the time of writing, editing, or contributing to the publications:
Dr. Nicholas Brandmeir - West Virginia University School of Medicine
Dr. Behnam Rezai Jahromi - University of Helsinki
Dr. Sumeet Vadera - University of California Irvine
Dr. Alexandra Paul - Albany Medical Center
Dr. Adnan Siddiqui - University at Buffalo
Jeffrey Garavaglia - West Virginia University School of Medicine
Twist-drill Craniostomy with Pressure-Controlled Fibrinolytic Irrigation Therapy Reduces Recurrence of Chronic Subdural Hematomas: Initial Experience in 16 Cases
April 2025 – Clinical Neurology and Neurosurgery
Roberto Doria-Medina, Marco Bissolo, Ralf Watzlawick, Mukesch Johannes Shah, Eva Rohr, Klaus-Jürgen Buttler, Jürgen Beck, & Roland Roelz
The following articles/clinical evidence describes some uses of IRRAflow that are not approved by the FDA, and the safety and effectiveness of any unapproved use(s) have not been established.
The FDA cleared indications of the IRRAflow Active Fluid Exchange System are as follows:
The use of IRRAflow Active Fluid Exchange System is indicated when intracranial pressure monitoring is required, and for externally draining intracranial fluid, as a means of reducing intracranial pressure in patients where an external drainage and monitoring system is needed.
For full information on contraindications and limitations, restrictions, cautions, warnings, or precautions in connection with the use of the IRRAflow Active Fluid Exchange System, please see the product Instructions for Use at https://www.clearpointneuro.com/irraflow/irraflow-eifus/
The following contributors to these publications were paid consultants who received compensation from IRRAS at the time of writing, editing, or contributing to the publications:
Dr. Nicholas Brandmeir - West Virginia University School of Medicine
Dr. Behnam Rezai Jahromi - University of Helsinki
Dr. Sumeet Vadera - University of California Irvine
Dr. Alexandra Paul - Albany Medical Center
Dr. Adnan Siddiqui - University at Buffalo
Jeffrey Garavaglia - West Virginia University School of Medicine
2024
An International, Multicenter Feasibility Study on Active and Continuous Irrigation With Cerebrospinal Fluid Exchange for Improving Outcomes in Cerebral Ventriculitis
July 2024 – Journal of Neurosurgery
Baig, Ammad A. MD; Hess, Ryan M. MD Sprau; Annelise C. MD, Kemeny, Hanna MD; Hashmi, Eisa B; Nazari, Pouya MD; Lim, Jaims MD; Turner, Ryan C. MD, PhD; Brandmeir, Nicholas MD, MS; Rezai Jahromi, Behnam MD; Niemelä, Mika MD, PhD; Jahromi, Babak S. MD, PhD; Levy, Elad I. MD, MBA; Siddiqui, & Adnan H. MD, PhD
This clinical literature is provided for information and educational purposes only. The administration of specific fluids and medications using the IRRAflow Active Fluid Exchange System is not approved by the FDA, and reflects the authors’ clinical opinions and findings. The IRRAflow Active Fluid Exchange System is intended to deliver physician directed fluids, and is not indicated for administration of specific medications. Any medication selection, dosage, and method of administration is determined solely by the treating physician in accordance with their clinical judgment and regulatory requirements.
The FDA cleared indications of the IRRAflow Active Fluid Exchange System are as follows:
The use of IRRAflow Active Fluid Exchange System is indicated when intracranial pressure monitoring is required, and for externally draining intracranial fluid, as a means of reducing intracranial pressure in patients where an external drainage and monitoring system is needed. The IRRAflow Active Fluid Exchange System is also intended to deliver physician directed fluids.
For full information on contraindications and limitations, restrictions, cautions, warnings, or precautions in connection with the use of the IRRAflow Active Fluid Exchange System, please see the product Instructions for Use at https://www.clearpointneuro.com/irraflow/irraflow-eifus/
The following contributors to these publications were paid consultants who received compensation from IRRAS at the time of writing, editing, or contributing to the publications.
Dr. Nicholas Brandmeir - West Virginia University School of Medicine
Dr. Behnam Rezai Jahromi - University of Helsinki
Dr. Sumeet Vadera - University of California Irvine
Dr. Alexandra Paul - Albany Medical Center
Dr. Adnan Siddiqui - University at Buffalo
Jeffrey Garavaglia - West Virginia University School of Medicine
Use of an Irrigating External Ventricular Drain in an Infant
June 2024 – World Neurosurgery
Kimberly Hamilton, Nick Brandmeir, & P. David Adelson
The following articles/clinical evidence describes some uses of IRRAflow that are not approved by the FDA, and the safety and effectiveness of any unapproved use(s) have not been established.
The FDA cleared indications of the IRRAflow Active Fluid Exchange System are as follows:
The use of IRRAflow Active Fluid Exchange System is indicated when intracranial pressure monitoring is required, and for externally draining intracranial fluid, as a means of reducing intracranial pressure in patients where an external drainage and monitoring system is needed.
For full information on contraindications and limitations, restrictions, cautions, warnings, or precautions in connection with the use of the IRRAflow Active Fluid Exchange System, please see the product Instructions for Use at https://www.clearpointneuro.com/irraflow/irraflow-eifus/
The following contributors to these publications were paid consultants who received compensation from IRRAS at the time of writing, editing, or contributing to the publications:
Dr. Nicholas Brandmeir - West Virginia University School of Medicine
Dr. Behnam Rezai Jahromi - University of Helsinki
Dr. Sumeet Vadera - University of California Irvine
Dr. Alexandra Paul - Albany Medical Center
Dr. Adnan Siddiqui - University at Buffalo
Jeffrey Garavaglia - West Virginia University School of Medicine
Continuous Intrathecal Milrinone Administration via IRRAflow
April 2024 – Neurology Journals
Hayley Williams, Joao Gomes, & Catherine Hassett
This clinical literature is provided for information and educational purposes only. The administration of specific fluids and medications using the IRRAflow Active Fluid Exchange System is not approved by the FDA, and reflects the authors’ clinical opinions and findings. The IRRAflow Active Fluid Exchange System is intended to deliver physician directed fluids, and is not indicated for administration of specific medications. Any medication selection, dosage, and method of administration is determined solely by the treating physician in accordance with their clinical judgment and regulatory requirements.
The FDA cleared indications of the IRRAflow Active Fluid Exchange System are as follows:
The use of IRRAflow Active Fluid Exchange System is indicated when intracranial pressure monitoring is required, and for externally draining intracranial fluid, as a means of reducing intracranial pressure in patients where an external drainage and monitoring system is needed. The IRRAflow Active Fluid Exchange System is also intended to deliver physician directed fluids.
For full information on contraindications and limitations, restrictions, cautions, warnings, or precautions in connection with the use of the IRRAflow Active Fluid Exchange System, please see the product Instructions for Use at https://www.clearpointneuro.com/irraflow/irraflow-eifus/
The following contributors to these publications were paid consultants who received compensation from IRRAS at the time of writing, editing, or contributing to the publications.
Dr. Nicholas Brandmeir - West Virginia University School of Medicine
Dr. Behnam Rezai Jahromi - University of Helsinki
Dr. Sumeet Vadera - University of California Irvine
Dr. Alexandra Paul - Albany Medical Center
Dr. Adnan Siddiqui - University at Buffalo
Jeffrey Garavaglia - West Virginia University School of Medicine
Stereotactic Placement of Dual Lumen Catheter System for Continuous Drainage, Irrigation, and Intraventricular Antibiotic Therapy for Treatment of Brain Abscess with Ventriculitis – A Case Report and Literature Review
February 2024 – Surgical Neurology International
Domenico Policicchio, Lucio Cosco, Giuseppe Mauro, Alfonso Nicola Iannello, Luigi Santaguida, Virginia Vescio, & Giosué Dipellegrini
This clinical literature is provided for information and educational purposes only. The administration of specific fluids and medications using the IRRAflow Active Fluid Exchange System is not approved by the FDA, and reflects the authors’ clinical opinions and findings. The IRRAflow Active Fluid Exchange System is intended to deliver physician directed fluids, and is not indicated for administration of specific medications. Any medication selection, dosage, and method of administration is determined solely by the treating physician in accordance with their clinical judgment and regulatory requirements.
The FDA cleared indications of the IRRAflow Active Fluid Exchange System are as follows:
The use of IRRAflow Active Fluid Exchange System is indicated when intracranial pressure monitoring is required, and for externally draining intracranial fluid, as a means of reducing intracranial pressure in patients where an external drainage and monitoring system is needed. The IRRAflow Active Fluid Exchange System is also intended to deliver physician directed fluids.
For full information on contraindications and limitations, restrictions, cautions, warnings, or precautions in connection with the use of the IRRAflow Active Fluid Exchange System, please see the product Instructions for Use at https://www.clearpointneuro.com/irraflow/irraflow-eifus/
The following contributors to these publications were paid consultants who received compensation from IRRAS at the time of writing, editing, or contributing to the publications.
Dr. Nicholas Brandmeir - West Virginia University School of Medicine
Dr. Behnam Rezai Jahromi - University of Helsinki
Dr. Sumeet Vadera - University of California Irvine
Dr. Alexandra Paul - Albany Medical Center
Dr. Adnan Siddiqui - University at Buffalo
Jeffrey Garavaglia - West Virginia University School of Medicine
2023
Continuous Irrigation with Thrombolytics for Intraventricular Hemorrhage: Case–Control Study
December 2023 – Neurosurgical Review
Diego A. Carrera, Marc C. Mabray, Michel T. Torbey, Jason E. Andrada, Danika E. Nelson, Preeyaporn Sarangarm, Heather Spader, Chad D. Cole, & Andrew P. Carlson
This clinical literature is provided for information and educational purposes only. The administration of specific fluids and medications using the IRRAflow Active Fluid Exchange System is not approved by the FDA, and reflects the authors’ clinical opinions and findings. The IRRAflow Active Fluid Exchange System is intended to deliver physician directed fluids, and is not indicated for administration of specific medications. Any medication selection, dosage, and method of administration is determined solely by the treating physician in accordance with their clinical judgment and regulatory requirements.
The FDA cleared indications of the IRRAflow Active Fluid Exchange System are as follows:
The use of IRRAflow Active Fluid Exchange System is indicated when intracranial pressure monitoring is required, and for externally draining intracranial fluid, as a means of reducing intracranial pressure in patients where an external drainage and monitoring system is needed. The IRRAflow Active Fluid Exchange System is also intended to deliver physician directed fluids.
For full information on contraindications and limitations, restrictions, cautions, warnings, or precautions in connection with the use of the IRRAflow Active Fluid Exchange System, please see the product Instructions for Use at https://www.clearpointneuro.com/irraflow/irraflow-eifus/
The following contributors to these publications were paid consultants who received compensation from IRRAS at the time of writing, editing, or contributing to the publications.
Dr. Nicholas Brandmeir - West Virginia University School of Medicine
Dr. Behnam Rezai Jahromi - University of Helsinki
Dr. Sumeet Vadera - University of California Irvine
Dr. Alexandra Paul - Albany Medical Center
Dr. Adnan Siddiqui - University at Buffalo
Jeffrey Garavaglia - West Virginia University School of Medicine
Treatment of Cerebral Ventriculitis with a New Self-Irrigating Catheter System: Narrative Review and Case Series
November 2023 – Journal of Anesthesia, Analgesia and Critical Care
Gloria Stati, Ernesto Migliorino, Manuel Moneti, Carlo Alberto Castioni, Antonino Scibilia, Giorgio Palandri, Giulio Virgili, & Raffaele Aspide
This clinical literature is provided for information and educational purposes only. The administration of specific fluids and medications using the IRRAflow Active Fluid Exchange System is not approved by the FDA, and reflects the authors’ clinical opinions and findings. The IRRAflow Active Fluid Exchange System is intended to deliver physician directed fluids, and is not indicated for administration of specific medications. Any medication selection, dosage, and method of administration is determined solely by the treating physician in accordance with their clinical judgment and regulatory requirements.
The FDA cleared indications of the IRRAflow Active Fluid Exchange System are as follows:
The use of IRRAflow Active Fluid Exchange System is indicated when intracranial pressure monitoring is required, and for externally draining intracranial fluid, as a means of reducing intracranial pressure in patients where an external drainage and monitoring system is needed. The IRRAflow Active Fluid Exchange System is also intended to deliver physician directed fluids.
For full information on contraindications and limitations, restrictions, cautions, warnings, or precautions in connection with the use of the IRRAflow Active Fluid Exchange System, please see the product Instructions for Use at https://www.clearpointneuro.com/irraflow/irraflow-eifus/
The following contributors to these publications were paid consultants who received compensation from IRRAS at the time of writing, editing, or contributing to the publications.
Dr. Nicholas Brandmeir - West Virginia University School of Medicine
Dr. Behnam Rezai Jahromi - University of Helsinki
Dr. Sumeet Vadera - University of California Irvine
Dr. Alexandra Paul - Albany Medical Center
Dr. Adnan Siddiqui - University at Buffalo
Jeffrey Garavaglia - West Virginia University School of Medicine
Continuous Intrathecal Medication Delivery with the IRRAflow Catheter: Pearls and Early Experience
October 2023 – Operative Neurosurgery
Jeffrey Garavaglia, PharmD, BCCCP, Trevor Hardigan, MD, Ryan Turner, MD, PhD, Gracie Monachello, Muhammad Babar Khan, MD, PhD, Johnie O. Hodge, MD, PhD, & Nicholas J. Brandmeir, MD, MS
This clinical literature is provided for information and educational purposes only. The administration of specific fluids and medications using the IRRAflow Active Fluid Exchange System is not approved by the FDA, and reflects the authors’ clinical opinions and findings. The IRRAflow Active Fluid Exchange System is intended to deliver physician directed fluids, and is not indicated for administration of specific medications. Any medication selection, dosage, and method of administration is determined solely by the treating physician in accordance with their clinical judgment and regulatory requirements.
The FDA cleared indications of the IRRAflow Active Fluid Exchange System are as follows:
The use of IRRAflow Active Fluid Exchange System is indicated when intracranial pressure monitoring is required, and for externally draining intracranial fluid, as a means of reducing intracranial pressure in patients where an external drainage and monitoring system is needed. The IRRAflow Active Fluid Exchange System is also intended to deliver physician directed fluids.
For full information on contraindications and limitations, restrictions, cautions, warnings, or precautions in connection with the use of the IRRAflow Active Fluid Exchange System, please see the product Instructions for Use at https://www.clearpointneuro.com/irraflow/irraflow-eifus/
The following contributors to these publications were paid consultants who received compensation from IRRAS at the time of writing, editing, or contributing to the publications.
Dr. Nicholas Brandmeir - West Virginia University School of Medicine
Dr. Behnam Rezai Jahromi - University of Helsinki
Dr. Sumeet Vadera - University of California Irvine
Dr. Alexandra Paul - Albany Medical Center
Dr. Adnan Siddiqui - University at Buffalo
Jeffrey Garavaglia - West Virginia University School of Medicine
HummingFlow: Novel Single Twist-Drill Access for Ventricular Drainage, Irrigation, Monitoring, and Automated Local Drug Delivery in Subarachnoid Hemorrhage
October 2023 – Journal of Neurosurgical Sciences
Diego A. Carrera, MD, Laura M. Marsh, FNP, Jessica J. Roach, RN, Preeyaporn Sarangarm, PharmD, Chad D. Cole, MD, Michel T. Torbey, MD, MBA, MPH, & Andrew P. Carlson, MD
This clinical literature is provided for information and educational purposes only. The administration of specific fluids and medications using the IRRAflow Active Fluid Exchange System is not approved by the FDA, and reflects the authors’ clinical opinions and findings. The IRRAflow Active Fluid Exchange System is intended to deliver physician directed fluids, and is not indicated for administration of specific medications. Any medication selection, dosage, and method of administration is determined solely by the treating physician in accordance with their clinical judgment and regulatory requirements.
The FDA cleared indications of the IRRAflow Active Fluid Exchange System are as follows:
The use of IRRAflow Active Fluid Exchange System is indicated when intracranial pressure monitoring is required, and for externally draining intracranial fluid, as a means of reducing intracranial pressure in patients where an external drainage and monitoring system is needed. The IRRAflow Active Fluid Exchange System is also intended to deliver physician directed fluids.
For full information on contraindications and limitations, restrictions, cautions, warnings, or precautions in connection with the use of the IRRAflow Active Fluid Exchange System, please see the product Instructions for Use at https://www.clearpointneuro.com/irraflow/irraflow-eifus/
The following contributors to these publications were paid consultants who received compensation from IRRAS at the time of writing, editing, or contributing to the publications.
Dr. Nicholas Brandmeir - West Virginia University School of Medicine
Dr. Behnam Rezai Jahromi - University of Helsinki
Dr. Sumeet Vadera - University of California Irvine
Dr. Alexandra Paul - Albany Medical Center
Dr. Adnan Siddiqui - University at Buffalo
Jeffrey Garavaglia - West Virginia University School of Medicine
Drainage, Irrigation, and Fibrinolytic Therapy (DRIFT) for Adult Intraventricular Hemorrhage Associated with Primary Hypertensive Hemorrhages Using IRRAflow Self-Irrigating Catheter
September 2023 – World Neurosurgery
Nicholas C. Field, Amanda J. Custozzo, Tessa A. Harland, Jared F. Sweeney, Matthew A. Adamo, John C. Dalfino, & Alexandra R. Paul
This clinical literature is provided for information and educational purposes only. The administration of specific fluids and medications using the IRRAflow Active Fluid Exchange System is not approved by the FDA, and reflects the authors’ clinical opinions and findings. The IRRAflow Active Fluid Exchange System is intended to deliver physician directed fluids, and is not indicated for administration of specific medications. Any medication selection, dosage, and method of administration is determined solely by the treating physician in accordance with their clinical judgment and regulatory requirements.
The FDA cleared indications of the IRRAflow Active Fluid Exchange System are as follows:
The use of IRRAflow Active Fluid Exchange System is indicated when intracranial pressure monitoring is required, and for externally draining intracranial fluid, as a means of reducing intracranial pressure in patients where an external drainage and monitoring system is needed. The IRRAflow Active Fluid Exchange System is also intended to deliver physician directed fluids.
For full information on contraindications and limitations, restrictions, cautions, warnings, or precautions in connection with the use of the IRRAflow Active Fluid Exchange System, please see the product Instructions for Use at https://www.clearpointneuro.com/irraflow/irraflow-eifus/
The following contributors to these publications were paid consultants who received compensation from IRRAS at the time of writing, editing, or contributing to the publications.
Dr. Nicholas Brandmeir - West Virginia University School of Medicine
Dr. Behnam Rezai Jahromi - University of Helsinki
Dr. Sumeet Vadera - University of California Irvine
Dr. Alexandra Paul - Albany Medical Center
Dr. Adnan Siddiqui - University at Buffalo
Jeffrey Garavaglia - West Virginia University School of Medicine
Use of Novel Automated Active Irrigation with Drainage Versus Passive Drainage Alone for Chronic Subdural Hematoma – A Propensity Score-Matched Comparative Study with Volumetric Analysis
June 2023 – Operative Neurosurgery
Baig, Ammad A. MD; Hess, Ryan M. MD; Khan, Asham MD; Cappuzzo, Justin M. MD; Turner, Ryan C. MD, PhD; Hashmi, Eisa BS; Bregy, Amade MD, PhD; Kuo, Cathleen C. BS; Nyabuto, Elizabeth MD; Goyal, Aditya D. High School Diploma; Davies, Jason M. MD, PhD; Levy, Elad I. MD, MBA; Siddiqui, Adnan H. MD, PhD
The following articles/clinical evidence describes some uses of IRRAflow that are not approved by the FDA, and the safety and effectiveness of any unapproved use(s) have not been established.
The FDA cleared indications of the IRRAflow Active Fluid Exchange System are as follows:
The use of IRRAflow Active Fluid Exchange System is indicated when intracranial pressure monitoring is required, and for externally draining intracranial fluid, as a means of reducing intracranial pressure in patients where an external drainage and monitoring system is needed.
For full information on contraindications and limitations, restrictions, cautions, warnings, or precautions in connection with the use of the IRRAflow Active Fluid Exchange System, please see the product Instructions for Use at https://www.clearpointneuro.com/irraflow/irraflow-eifus/
The following contributors to these publications were paid consultants who received compensation from IRRAS at the time of writing, editing, or contributing to the publications:
Dr. Nicholas Brandmeir - West Virginia University School of Medicine
Dr. Behnam Rezai Jahromi - University of Helsinki
Dr. Sumeet Vadera - University of California Irvine
Dr. Alexandra Paul - Albany Medical Center
Dr. Adnan Siddiqui - University at Buffalo
Jeffrey Garavaglia - West Virginia University School of Medicine
Thermal and Postural Effects on Fluid Mixing and Irrigation Patterns for Intraventricular Hemorrhage Treatment
January 2023 – Annals of Biomedical Engineering
Coskun Bilgi, Faisal Amlani, Heng Wei, Nick Rizzi, & Niema M. Pahlevan
The following articles/clinical evidence describes some uses of IRRAflow that are not approved by the FDA, and the safety and effectiveness of any unapproved use(s) have not been established.
The FDA cleared indications of the IRRAflow Active Fluid Exchange System are as follows:
The use of IRRAflow Active Fluid Exchange System is indicated when intracranial pressure monitoring is required, and for externally draining intracranial fluid, as a means of reducing intracranial pressure in patients where an external drainage and monitoring system is needed.
For full information on contraindications and limitations, restrictions, cautions, warnings, or precautions in connection with the use of the IRRAflow Active Fluid Exchange System, please see the product Instructions for Use at https://www.clearpointneuro.com/irraflow/irraflow-eifus/
The following contributors to these publications were paid consultants who received compensation from IRRAS at the time of writing, editing, or contributing to the publications:
Dr. Nicholas Brandmeir - West Virginia University School of Medicine
Dr. Behnam Rezai Jahromi - University of Helsinki
Dr. Sumeet Vadera - University of California Irvine
Dr. Alexandra Paul - Albany Medical Center
Dr. Adnan Siddiqui - University at Buffalo
Jeffrey Garavaglia - West Virginia University School of Medicine
2022
Continuous Tissue Plasminogen Activator Infusion Using a Minimally Invasive Irrigating Catheter for the Treatment of Intraparenchymal Hemorrhage Within the Basal Ganglia: Case Reports
September 2022 – Operative Neurosurgery
Samantha Varela, BS, Diego Carrera, MD, Ahmed Abd Elazim, MD Myranda B. Robinson, BS, Michel Torbey, MD, & Andrew P. Carlson, MD, MS-CR
This clinical literature is provided for information and educational purposes only. The administration of specific fluids and medications using the IRRAflow Active Fluid Exchange System is not approved by the FDA, and reflects the authors’ clinical opinions and findings. The IRRAflow Active Fluid Exchange System is intended to deliver physician directed fluids, and is not indicated for administration of specific medications. Any medication selection, dosage, and method of administration is determined solely by the treating physician in accordance with their clinical judgment and regulatory requirements.
The FDA cleared indications of the IRRAflow Active Fluid Exchange System are as follows:
The use of IRRAflow Active Fluid Exchange System is indicated when intracranial pressure monitoring is required, and for externally draining intracranial fluid, as a means of reducing intracranial pressure in patients where an external drainage and monitoring system is needed. The IRRAflow Active Fluid Exchange System is also intended to deliver physician directed fluids.
For full information on contraindications and limitations, restrictions, cautions, warnings, or precautions in connection with the use of the IRRAflow Active Fluid Exchange System, please see the product Instructions for Use at https://www.clearpointneuro.com/irraflow/irraflow-eifus/
The following contributors to these publications were paid consultants who received compensation from IRRAS at the time of writing, editing, or contributing to the publications.
Dr. Nicholas Brandmeir - West Virginia University School of Medicine
Dr. Behnam Rezai Jahromi - University of Helsinki
Dr. Sumeet Vadera - University of California Irvine
Dr. Alexandra Paul - Albany Medical Center
Dr. Adnan Siddiqui - University at Buffalo
Jeffrey Garavaglia - West Virginia University School of Medicine
Implementation of Irrigating Drainage Systems After Burr Hole Evacuation of Bilateral Subdural Hematomas Leads to Reduction in Postoperative Pneumocephalus and Improved Brain Re-expansion – A Case Report
July 2022 – Brain Hemorrhages
Alexander S. Himstead, Jordan L. Davies, Alvin Y. Chan, Diem Kieu Tran, Jefferson Chen, & Sumeet Vadera
The following articles/clinical evidence describes some uses of IRRAflow that are not approved by the FDA, and the safety and effectiveness of any unapproved use(s) have not been established.
The FDA cleared indications of the IRRAflow Active Fluid Exchange System are as follows:
The use of IRRAflow Active Fluid Exchange System is indicated when intracranial pressure monitoring is required, and for externally draining intracranial fluid, as a means of reducing intracranial pressure in patients where an external drainage and monitoring system is needed.
For full information on contraindications and limitations, restrictions, cautions, warnings, or precautions in connection with the use of the IRRAflow Active Fluid Exchange System, please see the product Instructions for Use at https://www.clearpointneuro.com/irraflow/irraflow-eifus/
The following contributors to these publications were paid consultants who received compensation from IRRAS at the time of writing, editing, or contributing to the publications:
Dr. Nicholas Brandmeir - West Virginia University School of Medicine
Dr. Behnam Rezai Jahromi - University of Helsinki
Dr. Sumeet Vadera - University of California Irvine
Dr. Alexandra Paul - Albany Medical Center
Dr. Adnan Siddiqui - University at Buffalo
Jeffrey Garavaglia - West Virginia University School of Medicine
IRRAflow Device Achieves Optimal Clearance of Intraventricular Hemorrhage (IVH) (AHA 2023)
February 2022 – Scientific Congress
Jennifer Wilson, Kanwar Bhinder, Shailesh Male, Richard Dalyai, Jennifer Griswold, Nurose Karim, & Vikram Bhinder
This clinical literature is provided for information and educational purposes only. The administration of specific fluids and medications using the IRRAflow Active Fluid Exchange System is not approved by the FDA, and reflects the authors’ clinical opinions and findings. The IRRAflow Active Fluid Exchange System is intended to deliver physician directed fluids, and is not indicated for administration of specific medications. Any medication selection, dosage, and method of administration is determined solely by the treating physician in accordance with their clinical judgment and regulatory requirements.
The FDA cleared indications of the IRRAflow Active Fluid Exchange System are as follows:
The use of IRRAflow Active Fluid Exchange System is indicated when intracranial pressure monitoring is required, and for externally draining intracranial fluid, as a means of reducing intracranial pressure in patients where an external drainage and monitoring system is needed. The IRRAflow Active Fluid Exchange System is also intended to deliver physician directed fluids.
For full information on contraindications and limitations, restrictions, cautions, warnings, or precautions in connection with the use of the IRRAflow Active Fluid Exchange System, please see the product Instructions for Use at https://www.clearpointneuro.com/irraflow/irraflow-eifus/
The following contributors to these publications were paid consultants who received compensation from IRRAS at the time of writing, editing, or contributing to the publications.
Dr. Nicholas Brandmeir - West Virginia University School of Medicine
Dr. Behnam Rezai Jahromi - University of Helsinki
Dr. Sumeet Vadera - University of California Irvine
Dr. Alexandra Paul - Albany Medical Center
Dr. Adnan Siddiqui - University at Buffalo
Jeffrey Garavaglia - West Virginia University School of Medicine
2021
Continuous Intraventricular Vancomycin for Treatment of Ventriculitis Using IRRAflow®: A Case Report
November 2021 – Surgical Neurology International
Ryan M. Hess, Asham Khan, Mallory Edwards, Adnan H. Siddiqui, & Elad I. Levy
This clinical literature is provided for information and educational purposes only. The administration of specific fluids and medications using the IRRAflow Active Fluid Exchange System is not approved by the FDA, and reflects the authors’ clinical opinions and findings. The IRRAflow Active Fluid Exchange System is intended to deliver physician directed fluids, and is not indicated for administration of specific medications. Any medication selection, dosage, and method of administration is determined solely by the treating physician in accordance with their clinical judgment and regulatory requirements.
The FDA cleared indications of the IRRAflow Active Fluid Exchange System are as follows:
The use of IRRAflow Active Fluid Exchange System is indicated when intracranial pressure monitoring is required, and for externally draining intracranial fluid, as a means of reducing intracranial pressure in patients where an external drainage and monitoring system is needed. The IRRAflow Active Fluid Exchange System is also intended to deliver physician directed fluids.
For full information on contraindications and limitations, restrictions, cautions, warnings, or precautions in connection with the use of the IRRAflow Active Fluid Exchange System, please see the product Instructions for Use at https://www.clearpointneuro.com/irraflow/irraflow-eifus/
The following contributors to these publications were paid consultants who received compensation from IRRAS at the time of writing, editing, or contributing to the publications.
Dr. Nicholas Brandmeir - West Virginia University School of Medicine
Dr. Behnam Rezai Jahromi - University of Helsinki
Dr. Sumeet Vadera - University of California Irvine
Dr. Alexandra Paul - Albany Medical Center
Dr. Adnan Siddiqui - University at Buffalo
Jeffrey Garavaglia - West Virginia University School of Medicine
Continuous Antibiotic Administration Using IRRAflow® Catheter for Treatment of Intracranial Abscess
October 2021 – Cureus
Ryan M. Hess, Audrey Lazar, David Smolar, Timothy E. O. Connor, Asham Khan, Adnan H. Siddiqui, & Elad I. Levy
This clinical literature is provided for information and educational purposes only. The administration of specific fluids and medications using the IRRAflow Active Fluid Exchange System is not approved by the FDA, and reflects the authors’ clinical opinions and findings. The IRRAflow Active Fluid Exchange System is intended to deliver physician directed fluids, and is not indicated for administration of specific medications. Any medication selection, dosage, and method of administration is determined solely by the treating physician in accordance with their clinical judgment and regulatory requirements.
The FDA cleared indications of the IRRAflow Active Fluid Exchange System are as follows:
The use of IRRAflow Active Fluid Exchange System is indicated when intracranial pressure monitoring is required, and for externally draining intracranial fluid, as a means of reducing intracranial pressure in patients where an external drainage and monitoring system is needed. The IRRAflow Active Fluid Exchange System is also intended to deliver physician directed fluids.
For full information on contraindications and limitations, restrictions, cautions, warnings, or precautions in connection with the use of the IRRAflow Active Fluid Exchange System, please see the product Instructions for Use at https://www.clearpointneuro.com/irraflow/irraflow-eifus/
The following contributors to these publications were paid consultants who received compensation from IRRAS at the time of writing, editing, or contributing to the publications.
Dr. Nicholas Brandmeir - West Virginia University School of Medicine
Dr. Behnam Rezai Jahromi - University of Helsinki
Dr. Sumeet Vadera - University of California Irvine
Dr. Alexandra Paul - Albany Medical Center
Dr. Adnan Siddiqui - University at Buffalo
Jeffrey Garavaglia - West Virginia University School of Medicine
Use of Automated Irrigating Drainage System in Six Patients With Chronic Subdural Hematoma: A Single-Center Experience
August 2021 – Cureus
Jordan Davies, Alexander S. Himstead, Ji Hyun Kim, Alvin Y. Chan, Diem Kieu Tran, Frank P. Hsu, & Sumeet Vadera
The following articles/clinical evidence describes some uses of IRRAflow that are not approved by the FDA, and the safety and effectiveness of any unapproved use(s) have not been established.
The FDA cleared indications of the IRRAflow Active Fluid Exchange System are as follows:
The use of IRRAflow Active Fluid Exchange System is indicated when intracranial pressure monitoring is required, and for externally draining intracranial fluid, as a means of reducing intracranial pressure in patients where an external drainage and monitoring system is needed.
For full information on contraindications and limitations, restrictions, cautions, warnings, or precautions in connection with the use of the IRRAflow Active Fluid Exchange System, please see the product Instructions for Use at https://www.clearpointneuro.com/irraflow/irraflow-eifus/
The following contributors to these publications were paid consultants who received compensation from IRRAS at the time of writing, editing, or contributing to the publications:
Dr. Nicholas Brandmeir - West Virginia University School of Medicine
Dr. Behnam Rezai Jahromi - University of Helsinki
Dr. Sumeet Vadera - University of California Irvine
Dr. Alexandra Paul - Albany Medical Center
Dr. Adnan Siddiqui - University at Buffalo
Jeffrey Garavaglia - West Virginia University School of Medicine
Active Cerebrospinal Fluid Exchange System for Treatment of Pyogenic Ventriculitis
June 2021 – Neurosurgery Open
Behnam Rezai Jahromi, MD, Päivi Tanskanen, MD, Anniina Koski-Pàlken, MD, PhD, Christoph Schwartz, MD, MHBA, Päivi Koroknay-Pal, MD, PhD, Inka Romo, MD, PhD, Mika Niemelä, MD, PhD , & Jari Siironen, MD, PhD
This clinical literature is provided for information and educational purposes only. The administration of specific fluids and medications using the IRRAflow Active Fluid Exchange System is not approved by the FDA, and reflects the authors’ clinical opinions and findings. The IRRAflow Active Fluid Exchange System is intended to deliver physician directed fluids, and is not indicated for administration of specific medications. Any medication selection, dosage, and method of administration is determined solely by the treating physician in accordance with their clinical judgment and regulatory requirements.
The FDA cleared indications of the IRRAflow Active Fluid Exchange System are as follows:
The use of IRRAflow Active Fluid Exchange System is indicated when intracranial pressure monitoring is required, and for externally draining intracranial fluid, as a means of reducing intracranial pressure in patients where an external drainage and monitoring system is needed. The IRRAflow Active Fluid Exchange System is also intended to deliver physician directed fluids.
For full information on contraindications and limitations, restrictions, cautions, warnings, or precautions in connection with the use of the IRRAflow Active Fluid Exchange System, please see the product Instructions for Use at https://www.clearpointneuro.com/irraflow/irraflow-eifus/
The following contributors to these publications were paid consultants who received compensation from IRRAS at the time of writing, editing, or contributing to the publications.
Dr. Nicholas Brandmeir - West Virginia University School of Medicine
Dr. Behnam Rezai Jahromi - University of Helsinki
Dr. Sumeet Vadera - University of California Irvine
Dr. Alexandra Paul - Albany Medical Center
Dr. Adnan Siddiqui - University at Buffalo
Jeffrey Garavaglia - West Virginia University School of Medicine
Net Drainage as a Novel Metric for Irrigating Drainage Systems in Chronic Subdural Hematoma Management – A Case Report
June 2021 – Operative Neurosurgery
Alexander S. Himstead, BS, Jordan Davies, MD, Diem Kieu Tran, MD, & Sumeet Vadera, MD
The following articles/clinical evidence describes some uses of IRRAflow that are not approved by the FDA, and the safety and effectiveness of any unapproved use(s) have not been established.
The FDA cleared indications of the IRRAflow Active Fluid Exchange System are as follows:
The use of IRRAflow Active Fluid Exchange System is indicated when intracranial pressure monitoring is required, and for externally draining intracranial fluid, as a means of reducing intracranial pressure in patients where an external drainage and monitoring system is needed.
For full information on contraindications and limitations, restrictions, cautions, warnings, or precautions in connection with the use of the IRRAflow Active Fluid Exchange System, please see the product Instructions for Use at https://www.clearpointneuro.com/irraflow/irraflow-eifus/
The following contributors to these publications were paid consultants who received compensation from IRRAS at the time of writing, editing, or contributing to the publications:
Dr. Nicholas Brandmeir - West Virginia University School of Medicine
Dr. Behnam Rezai Jahromi - University of Helsinki
Dr. Sumeet Vadera - University of California Irvine
Dr. Alexandra Paul - Albany Medical Center
Dr. Adnan Siddiqui - University at Buffalo
Jeffrey Garavaglia - West Virginia University School of Medicine
Drainage, Irrigation, and Fibrinolytic Therapy (DRIFT) for Adult Intraventricular Hemorrhage Using IRRAflow® Self-Irrigating Catheter
June 2021 – Cureus
Kenan Rajjoub, Ryan M. Hess, Timothy E. O'Connor, Asham Khan, Adnan H. Siddiqui, & Elad I. Levy
This clinical literature is provided for information and educational purposes only. The administration of specific fluids and medications using the IRRAflow Active Fluid Exchange System is not approved by the FDA, and reflects the authors’ clinical opinions and findings. The IRRAflow Active Fluid Exchange System is intended to deliver physician directed fluids, and is not indicated for administration of specific medications. Any medication selection, dosage, and method of administration is determined solely by the treating physician in accordance with their clinical judgment and regulatory requirements.
The FDA cleared indications of the IRRAflow Active Fluid Exchange System are as follows:
The use of IRRAflow Active Fluid Exchange System is indicated when intracranial pressure monitoring is required, and for externally draining intracranial fluid, as a means of reducing intracranial pressure in patients where an external drainage and monitoring system is needed. The IRRAflow Active Fluid Exchange System is also intended to deliver physician directed fluids.
For full information on contraindications and limitations, restrictions, cautions, warnings, or precautions in connection with the use of the IRRAflow Active Fluid Exchange System, please see the product Instructions for Use at https://www.clearpointneuro.com/irraflow/irraflow-eifus/
The following contributors to these publications were paid consultants who received compensation from IRRAS at the time of writing, editing, or contributing to the publications.
Dr. Nicholas Brandmeir - West Virginia University School of Medicine
Dr. Behnam Rezai Jahromi - University of Helsinki
Dr. Sumeet Vadera - University of California Irvine
Dr. Alexandra Paul - Albany Medical Center
Dr. Adnan Siddiqui - University at Buffalo
Jeffrey Garavaglia - West Virginia University School of Medicine
Minimally Invasive Approach to Subdural Hematoma Treatment Using IRRAflow Catheter and Middle Meningeal Artery Embolization
June 2021 – Cureus
Ryan M. Hess, Timothy E. O'Connor, Asham Khan, Adnan H. Siddiqui, & Jason Davies
The following articles/clinical evidence describes some uses of IRRAflow that are not approved by the FDA, and the safety and effectiveness of any unapproved use(s) have not been established.
The FDA cleared indications of the IRRAflow Active Fluid Exchange System are as follows:
The use of IRRAflow Active Fluid Exchange System is indicated when intracranial pressure monitoring is required, and for externally draining intracranial fluid, as a means of reducing intracranial pressure in patients where an external drainage and monitoring system is needed.
For full information on contraindications and limitations, restrictions, cautions, warnings, or precautions in connection with the use of the IRRAflow Active Fluid Exchange System, please see the product Instructions for Use at https://www.clearpointneuro.com/irraflow/irraflow-eifus/
The following contributors to these publications were paid consultants who received compensation from IRRAS at the time of writing, editing, or contributing to the publications:
Dr. Nicholas Brandmeir - West Virginia University School of Medicine
Dr. Behnam Rezai Jahromi - University of Helsinki
Dr. Sumeet Vadera - University of California Irvine
Dr. Alexandra Paul - Albany Medical Center
Dr. Adnan Siddiqui - University at Buffalo
Jeffrey Garavaglia - West Virginia University School of Medicine
2019
Novel Use of Dual-Lumen Catheter for Irrigation and Drainage After Evacuation of Chronic Subdural Hematoma
June 2019 – World Neurosurgery
Diem Kieu Tran, Peter Tretiakov, Julia Brock, Jefferson Chen, & Sumeet Vadera
The following articles/clinical evidence describes some uses of IRRAflow that are not approved by the FDA, and the safety and effectiveness of any unapproved use(s) have not been established.
The FDA cleared indications of the IRRAflow Active Fluid Exchange System are as follows:
The use of IRRAflow Active Fluid Exchange System is indicated when intracranial pressure monitoring is required, and for externally draining intracranial fluid, as a means of reducing intracranial pressure in patients where an external drainage and monitoring system is needed.
For full information on contraindications and limitations, restrictions, cautions, warnings, or precautions in connection with the use of the IRRAflow Active Fluid Exchange System, please see the product Instructions for Use at https://www.clearpointneuro.com/irraflow/irraflow-eifus/
The following contributors to these publications were paid consultants who received compensation from IRRAS at the time of writing, editing, or contributing to the publications:
Dr. Nicholas Brandmeir - West Virginia University School of Medicine
Dr. Behnam Rezai Jahromi - University of Helsinki
Dr. Sumeet Vadera - University of California Irvine
Dr. Alexandra Paul - Albany Medical Center
Dr. Adnan Siddiqui - University at Buffalo
Jeffrey Garavaglia - West Virginia University School of Medicine
2012
Innovative Approach for Prevention and Treatment of Post Subarachnoid Hemorrhage Vasospasm: A Preliminary Report
June 2012 – Asian Journal of Neurosurgery
Neelam K. Venkataramana, Shailesh A.V. Rao, Arun L. Naik, Kishore Shetty, Paparaja Murthy, Abhilash Bansal, & Christos Panotopoulos
This clinical literature is provided for information and educational purposes only. The administration of specific fluids and medications using the IRRAflow Active Fluid Exchange System is not approved by the FDA, and reflects the authors’ clinical opinions and findings. The IRRAflow Active Fluid Exchange System is intended to deliver physician directed fluids, and is not indicated for administration of specific medications. Any medication selection, dosage, and method of administration is determined solely by the treating physician in accordance with their clinical judgment and regulatory requirements.
The FDA cleared indications of the IRRAflow Active Fluid Exchange System are as follows:
The use of IRRAflow Active Fluid Exchange System is indicated when intracranial pressure monitoring is required, and for externally draining intracranial fluid, as a means of reducing intracranial pressure in patients where an external drainage and monitoring system is needed. The IRRAflow Active Fluid Exchange System is also intended to deliver physician directed fluids.
For full information on contraindications and limitations, restrictions, cautions, warnings, or precautions in connection with the use of the IRRAflow Active Fluid Exchange System, please see the product Instructions for Use at https://www.clearpointneuro.com/irraflow/irraflow-eifus/
The following contributors to these publications were paid consultants who received compensation from IRRAS at the time of writing, editing, or contributing to the publications.
Dr. Nicholas Brandmeir - West Virginia University School of Medicine
Dr. Behnam Rezai Jahromi - University of Helsinki
Dr. Sumeet Vadera - University of California Irvine
Dr. Alexandra Paul - Albany Medical Center
Dr. Adnan Siddiqui - University at Buffalo
Jeffrey Garavaglia - West Virginia University School of Medicine
Additional Educational Materials
IVH Decision Tree – Active Fluid Exchange
Workflows
This reference material is provided for information and educational purposes only. The administration of specific fluids and medications using the IRRAflow Active Fluid Exchange System is not cleared by the FDA, and reflects the authors’ clinical opinions and findings. The IRRAflow Active Fluid Exchange System is intended to deliver physician directed fluids, and is not indicated for administration of specific medications. Any medication selection, dosage, and method of administration is determined solely by the treating physician in accordance with their clinical judgment and regulatory requirements.
The FDA cleared indications of the IRRAflow Active Fluid Exchange System are as follows:
The use of IRRAflow Active Fluid Exchange System is indicated when intracranial pressure monitoring is required, and for externally draining intracranial fluid, as a means of reducing intracranial pressure in patients where an external drainage and monitoring system is needed.
The IRRAflow Active Fluid Exchange System is also intended to deliver physician directed fluids.
For full information on contraindications and limitations, restrictions, cautions, warnings, or precautions in connection with the use of the IRRAflow Active Fluid Exchange System, please see the product Instructions for Use at https://www.clearpointneuro.com/irraflow/irraflow-eifus/
The ACE Society received financial support from IRRAS. IRRAS did not control the content of the reference material. The views expressed are those of the authors.
The following officers and former officers of the ACE Society were paid consultants who have received compensation from IRRAS.
Dr. Nicholas Brandmeir - West Virginia University School of Medicine
Dr. Behnam Rezai Jahromi - University of Helsinki
Dr. Alexandra Paul - Albany Medical Center
Dr. Adnan Siddiqui - University at Buffalo
SAH Decision Tree – Active Fluid Exchange
Workflows
This reference material is provided for information and educational purposes only. The administration of specific fluids and medications using the IRRAflow Active Fluid Exchange System is not cleared by the FDA, and reflects the authors’ clinical opinions and findings. The IRRAflow Active Fluid Exchange System is intended to deliver physician directed fluids, and is not indicated for administration of specific medications. Any medication selection, dosage, and method of administration is determined solely by the treating physician in accordance with their clinical judgment and regulatory requirements.
The FDA cleared indications of the IRRAflow Active Fluid Exchange System are as follows:
The use of IRRAflow Active Fluid Exchange System is indicated when intracranial pressure monitoring is required, and for externally draining intracranial fluid, as a means of reducing intracranial pressure in patients where an external drainage and monitoring system is needed.
The IRRAflow Active Fluid Exchange System is also intended to deliver physician directed fluids.
For full information on contraindications and limitations, restrictions, cautions, warnings, or precautions in connection with the use of the IRRAflow Active Fluid Exchange System, please see the product Instructions for Use at https://www.clearpointneuro.com/irraflow/irraflow-eifus/
The ACE Society received financial support from IRRAS. IRRAS did not control the content of the reference material. The views expressed are those of the authors.
The following officers and former officers of the ACE Society were paid consultants who have received compensation from IRRAS.
Dr. Nicholas Brandmeir - West Virginia University School of Medicine
Dr. Behnam Rezai Jahromi - University of Helsinki
Dr. Alexandra Paul - Albany Medical Center
Dr. Adnan Siddiqui - University at Buffalo
Ventriculitis Decision Tree – Active Fluid Exchange
Workflows
This reference material is provided for information and educational purposes only. The administration of specific fluids and medications using the IRRAflow Active Fluid Exchange System is not cleared by the FDA, and reflects the authors’ clinical opinions and findings. The IRRAflow Active Fluid Exchange System is intended to deliver physician directed fluids, and is not indicated for administration of specific medications. Any medication selection, dosage, and method of administration is determined solely by the treating physician in accordance with their clinical judgment and regulatory requirements.
The FDA cleared indications of the IRRAflow Active Fluid Exchange System are as follows:
The use of IRRAflow Active Fluid Exchange System is indicated when intracranial pressure monitoring is required, and for externally draining intracranial fluid, as a means of reducing intracranial pressure in patients where an external drainage and monitoring system is needed.
The IRRAflow Active Fluid Exchange System is also intended to deliver physician directed fluids.
For full information on contraindications and limitations, restrictions, cautions, warnings, or precautions in connection with the use of the IRRAflow Active Fluid Exchange System, please see the product Instructions for Use at https://www.clearpointneuro.com/irraflow/irraflow-eifus/
The ACE Society received financial support from IRRAS. IRRAS did not control the content of the reference material. The views expressed are those of the authors.
The following officers and former officers of the ACE Society were paid consultants who have received compensation from IRRAS.
Dr. Nicholas Brandmeir - West Virginia University School of Medicine
Dr. Behnam Rezai Jahromi - University of Helsinki
Dr. Alexandra Paul - Albany Medical Center
Dr. Adnan Siddiqui - University at Buffalo
IRRAflow Orders Workflows
This reference material is provided for information and educational purposes only. The administration of specific fluids and medications using the IRRAflow Active Fluid Exchange System is not cleared by the FDA, and reflects the authors’ clinical opinions and findings. The IRRAflow Active Fluid Exchange System is intended to deliver physician directed fluids, and is not indicated for administration of specific medications. Any medication selection, dosage, and method of administration is determined solely by the treating physician in accordance with their clinical judgment and regulatory requirements.
The FDA cleared indications of the IRRAflow Active Fluid Exchange System are as follows:
The use of IRRAflow Active Fluid Exchange System is indicated when intracranial pressure monitoring is required, and for externally draining intracranial fluid, as a means of reducing intracranial pressure in patients where an external drainage and monitoring system is needed.
The IRRAflow Active Fluid Exchange System is also intended to deliver physician directed fluids.
For full information on contraindications and limitations, restrictions, cautions, warnings, or precautions in connection with the use of the IRRAflow Active Fluid Exchange System, please see the product Instructions for Use at https://www.clearpointneuro.com/irraflow/irraflow-eifus/
The ACE Society received financial support from IRRAS. IRRAS did not control the content of the reference material. The views expressed are those of the authors.
The following officers and former officers of the ACE Society were paid consultants who have received compensation from IRRAS.
Dr. Nicholas Brandmeir - West Virginia University School of Medicine
Dr. Behnam Rezai Jahromi - University of Helsinki
Dr. Alexandra Paul - Albany Medical Center
Dr. Adnan Siddiqui - University at Buffalo
IRRAflow Orders Workflow Example
This reference material is provided for information and educational purposes only. The administration of specific fluids and medications using the IRRAflow Active Fluid Exchange System is not cleared by the FDA, and reflects the authors’ clinical opinions and findings. The IRRAflow Active Fluid Exchange System is intended to deliver physician directed fluids, and is not indicated for administration of specific medications. Any medication selection, dosage, and method of administration is determined solely by the treating physician in accordance with their clinical judgment and regulatory requirements.
The FDA cleared indications of the IRRAflow Active Fluid Exchange System are as follows:
The use of IRRAflow Active Fluid Exchange System is indicated when intracranial pressure monitoring is required, and for externally draining intracranial fluid, as a means of reducing intracranial pressure in patients where an external drainage and monitoring system is needed.
The IRRAflow Active Fluid Exchange System is also intended to deliver physician directed fluids.
For full information on contraindications and limitations, restrictions, cautions, warnings, or precautions in connection with the use of the IRRAflow Active Fluid Exchange System, please see the product Instructions for Use at https://www.clearpointneuro.com/irraflow/irraflow-eifus/
The ACE Society received financial support from IRRAS. IRRAS did not control the content of the reference material. The views expressed are those of the authors.
The following officers and former officers of the ACE Society were paid consultants who have received compensation from IRRAS.
Dr. Nicholas Brandmeir - West Virginia University School of Medicine
Dr. Behnam Rezai Jahromi - University of Helsinki
Dr. Alexandra Paul - Albany Medical Center
Dr. Adnan Siddiqui - University at Buffalo
Learn More About Us
PROVIDING COMPREHENSIVE NEUROSURGICAL SOLUTIONS
Introducing IRRAflow IRRAflow Training Videos IRRAflow e-IFUs